Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients With Mucopolysaccharidosis Type I Hurler-Scheie and Scheie

NCT05682144 is registered in ClinicalTrials.gov with Immusoft of CA, Inc. as lead sponsor.

NCT NCT05682144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05682144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients With Mucopolysaccharidosis Type I Hurler-Scheie and Scheie
Lead sponsor
Immusoft of CA, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 12, 2023
Completion date
June 1, 2044
Enrollment
11 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mucopolysaccharidosis ih/s, mucopolysaccharidosis is